Parameter
| Biomarker | Akkermansia muciniphila (Akk bacteria) | Full name | Akkermansia muciniphila | Molecular Type | Bacteria (Verrucomicrobia) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Assessment of intestinal barrier function | ||
| Disease | Inflammatory Bowel Disease (IBD) | Disease Subtypes | / | ||
| Organ | Intestine | Test Sample / Technology Platform | Fecal/ileal mucosal biopsy (16S rRNA sequencing, qPCR, fluorescence in situ hybridization, metagenomic sequencing) | ||
| Pathobiological Mechanisms | 1. It can degrade intestinal mucus laminin (MUC2), produce SCFA such as acetic acid and propionic acid, and enhance the integrity of intestinal epithelial tight junctions (occludin and ZO-1); (2) The abundance of Akk bacteria in the ileum mucosa of CD patients decreased by 55% compared with that of healthy people, leading to the thinning of mucus layer (thickness < 5μm) and the increase of intestinal permeability; (3) The recovery of intestinal flora abundance (> 3% of total intestinal flora) was positively correlated with the duration of anti-TNF therapy in CD patients (r=0.68). | ||||
| Clinical Availability Status | Application in clinical research | ||||
| Notes and Dynamics | 1. The addition of an oral Akk bacterial formulation to infliximab increased the 1-year remission maintenance rate by 35% in CD patients (preliminary Cell Host Microbe data 2025); (2) A real-time Akk bacterial abundance monitoring chip is being developed, which can realize personalized adjustment of treatment regimens for CD patients and reduce ineffective treatment | ||||